NMPA
国家药品监督管理局
China
Last reviewed 2026-08-05
国家药监局通过CMDE（医疗器械技术审评中心）进行技术审评来监管医疗器械。中国采用三级风险分类体系。外国制造商必须指定上市许可持有人（MAH），II类和III类器械需完成境内检测。中国是全球第二大医疗器械市场。
NMPA STRUCTURE AND MARKET IMPORTANCE
NMPA (formerly CFDA) is China’s national authority for medical devices, drugs, and cosmetics. Technical review of higher-risk devices is led by CMDE. China is the world’s second-largest device market, so NMPA strategy often sits beside FDA/EU MDR in multi-market launch plans. Rules evolve quickly around clinical evaluation, unique device identification, and MAH accountability.
REGISTRATION PATHWAY AT A GLANCE
Class I devices generally use filing/notification. Class II and III require registration dossiers, type testing at NMPA-recognized labs, and often clinical evidence depending on catalogue rules. Foreign manufacturers must work through a Chinese Marketing Authorization Holder (MAH) that holds the certificate and post-market duties—unlike FDA clearances that a foreign firm can hold with a US agent model.
TIMELINES AND COMMON BOTTLENECKS
Class II often takes roughly 6–12 months and Class III 12–24+ months after a complete package, with clinical trials adding years when required. Bottlenecks include incomplete Chinese-language documentation, unexpected classification differences vs FDA/EU, and testing queue times. Cross-mapping product codes early reduces rework.
POST-MARKET AND VIGILANCE
After approval, MAHs manage adverse event reporting, re-registration cycles, and manufacturing change notifications. Surveillance actions and standards updates can affect devices already on market. Global RA teams should watch NMPA notices in parallel with FDA recalls and EU FSCA signals for multi-region products.
器械分类
Class I, II, III
审批路径
NMPA Registration (CMDE review)
核心监管职能
- ▸CMDE技术审评
- ▸MAH（上市许可持有人）制度
- ▸境内检测要求
- ▸临床试验监管
- ▸NMPA注册证
§ RELATED INTELLIGENCE
§ FAQ
What is NMPA in China?
The NMPA (National Medical Products Administration) is China's national regulatory authority for medical devices, drugs, and cosmetics. Formerly known as CFDA, it oversees device registration, market surveillance, and post-market safety through its technical review body CMDE (Center for Medical Device Evaluation). China is the world's second-largest medical device market.
How do I register a medical device with NMPA?
NMPA registration requires appointing a Marketing Authorization Holder (MAH) in China, completing in-country testing at a NMPA-recognized laboratory for Class II and III devices, submitting a technical dossier to CMDE for review, and obtaining a registration certificate. Foreign manufacturers cannot hold the registration directly — a Chinese MAH entity is mandatory.
What are NMPA medical device classification requirements?
China uses a three-class risk-based system. Class I (lowest risk) requires filing notification with local authorities. Class II (moderate risk) requires registration with provincial-level NMPA. Class III (highest risk) requires registration with national NMPA through CMDE review. Classification is determined by the NMPA Classification Catalogue, which may differ from FDA or EU classifications for the same device.
How long does NMPA medical device approval take?
NMPA approval timelines vary by device class. Class I notification typically takes 1–2 months. Class II registration takes 6–12 months. Class III registration takes 12–24+ months due to CMDE technical review complexity. Clinical trials, if required, can add 1–3 additional years. In-country testing alone typically requires 3–6 months.
Do foreign manufacturers need a local representative for NMPA?
Yes. Foreign manufacturers must appoint a Marketing Authorization Holder (MAH) — a Chinese legal entity responsible for the device registration, post-market surveillance, and regulatory compliance in China. The MAH holds the registration certificate and bears legal responsibility. This is one of the most significant differences from FDA registration, where foreign manufacturers can hold their own clearances through a US Agent.
MedFlux实时监控NMPA的监管变化、安全警报和市场信号——让您的团队不错过任何关键更新。
免费监控{abbr} →